{"id":"haic-of-folfox","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL3142236","moleculeType":"Small molecule","molecularWeight":"928.10"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HAIC is an interventional oncology technique that infuses chemotherapy agents directly into the hepatic artery supplying the tumor, maximizing local drug exposure while minimizing systemic toxicity. FOLFOX is a combination regimen of 5-fluorouracil, leucovorin, and oxaliplatin that inhibits DNA synthesis and repair. This combination approach leverages regional delivery to enhance efficacy in hepatocellular carcinoma and other liver malignancies.","oneSentence":"HAIC (hepatic arterial infusion chemotherapy) of FOLFOX delivers chemotherapy directly into the hepatic artery to treat liver cancers with high local drug concentration.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:40:07.933Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma"},{"name":"Advanced liver cancer"}]},"trialDetails":[{"nctId":"NCT07466238","phase":"NA","title":"HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2026-03-15","conditions":"Biliary Tract Cancer (BTC)","enrollment":40},{"nctId":"NCT07483359","phase":"PHASE2","title":"Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus","status":"NOT_YET_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2026-03","conditions":"Hepatocellular Carcinoma (HCC), Portal Vein Tumor Thrombus","enrollment":38},{"nctId":"NCT04945720","phase":"PHASE2","title":"Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2022-04-11","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT07380633","phase":"PHASE2","title":"Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-23","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":90},{"nctId":"NCT06631326","phase":"","title":"HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)","status":"COMPLETED","sponsor":"First Hospital of China Medical University","startDate":"2021-01-01","conditions":"HCC - Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy, BCLC Stage C Hepatocellular Carcinoma","enrollment":244},{"nctId":"NCT05198609","phase":"PHASE3","title":"Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-01-17","conditions":"Hepatocellular Carcinoma","enrollment":214},{"nctId":"NCT07328009","phase":"PHASE2","title":"A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-25","conditions":"Hepato Cellular Carcinoma (HCC)","enrollment":350},{"nctId":"NCT07353827","phase":"PHASE2","title":"FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Hepatic Arterial Infusion Chemotherapy","enrollment":36},{"nctId":"NCT05171166","phase":"PHASE2, PHASE3","title":"Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.","status":"TERMINATED","sponsor":"Peking University","startDate":"2021-12-24","conditions":"Hepatocellular Carcinoma","enrollment":18},{"nctId":"NCT07272265","phase":"NA","title":"The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2020-10-28","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":300},{"nctId":"NCT06172205","phase":"PHASE3","title":"Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-07-01","conditions":"BCLC Stage C Hepatocellular Carcinoma, Chemotherapy Effect","enrollment":262},{"nctId":"NCT05751343","phase":"PHASE2","title":"Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-03-09","conditions":"Hepatocellular Carcinoma","enrollment":55},{"nctId":"NCT06467799","phase":"PHASE2","title":"Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-09-01","conditions":"Hepatocellular Carcinoma, Beyond Milan Criteria","enrollment":39},{"nctId":"NCT06323382","phase":"","title":"Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-01-01","conditions":"Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab","enrollment":240},{"nctId":"NCT06031285","phase":"PHASE2","title":"Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-09-01","conditions":"Hepatocellular Carcinoma","enrollment":43},{"nctId":"NCT06893887","phase":"NA","title":"Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Nanjing Tianyinshan Hospital","startDate":"2025-05-22","conditions":"Hepatocellular Carcinoma(HCC)","enrollment":300},{"nctId":"NCT07012798","phase":"PHASE2","title":"FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-06-30","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":30},{"nctId":"NCT06988852","phase":"PHASE2","title":"FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-05-01","conditions":"Colorectal Liver Metastasis (CRLM)","enrollment":300},{"nctId":"NCT06904183","phase":"PHASE2","title":"Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2025-04-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":320},{"nctId":"NCT06904014","phase":"PHASE2","title":"Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC","status":"RECRUITING","sponsor":"Lei ZHAO","startDate":"2023-10-25","conditions":"HCC","enrollment":40},{"nctId":"NCT06641713","phase":"","title":"HAIC Compared With TACE in Huge Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-10-01","conditions":"Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer","enrollment":664},{"nctId":"NCT06860490","phase":"PHASE2","title":"HAIC Combined with Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-18","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":164},{"nctId":"NCT05713994","phase":"","title":"Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Ze-yang Ding, MD","startDate":"2020-05-19","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT06333561","phase":"","title":"HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-01-01","conditions":"Hepatocellular Carcinoma, Lenvatinib, PD-1 Inhibitor","enrollment":300},{"nctId":"NCT06492395","phase":"PHASE3","title":"Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2024-08-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":178},{"nctId":"NCT06742424","phase":"PHASE2","title":"PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-10-01","conditions":"Hepato Cellular Carcinoma (HCC)","enrollment":36},{"nctId":"NCT06737913","phase":"PHASE2","title":"HAI or IV of Adebrelimab, Combined with Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-12","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":78},{"nctId":"NCT06187961","phase":"PHASE2","title":"Combined HAIC, Lenvatinib and Cadonilimab As Conversion Therapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-12-07","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":36},{"nctId":"NCT06609863","phase":"NA","title":"dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-10-01","conditions":"Advanced Hepatocellular Carcinoma, Atezolizumab, Bevacizumab","enrollment":27},{"nctId":"NCT03869034","phase":"PHASE2","title":"HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-03-25","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT06632106","phase":"","title":"HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2024-08-16","conditions":"Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor, Immune Checkpoint Inhibitors","enrollment":97},{"nctId":"NCT06632093","phase":"","title":"HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC","status":"RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2024-09-16","conditions":"BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy","enrollment":84},{"nctId":"NCT06061276","phase":"NA","title":"bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-05-20","conditions":"Liver Diseases, Hepatocellular Carcinoma, Immunotherapy","enrollment":40},{"nctId":"NCT06070636","phase":"NA","title":"bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-05-20","conditions":"Liver Diseases, Hepatocellular Carcinoma, Immunotherapy","enrollment":30},{"nctId":"NCT06519578","phase":"NA","title":"Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-08-01","conditions":"Hepatocellular Carcinoma","enrollment":1115},{"nctId":"NCT06405061","phase":"PHASE2","title":"Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-05-01","conditions":"Adebrelimab, Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT06406634","phase":"PHASE2","title":"Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Hunan Cancer Hospital","startDate":"2024-05-15","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT06375486","phase":"PHASE2","title":"Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-03-14","conditions":"Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT06375317","phase":"PHASE2","title":"HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure","status":"NOT_YET_RECRUITING","sponsor":"Yehua Shen","startDate":"2024-04-30","conditions":"HCC - Hepatocellular Carcinoma","enrollment":42},{"nctId":"NCT06370065","phase":"PHASE2","title":"Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-27","conditions":"Advanced Hepatocellular Carcinoma","enrollment":35},{"nctId":"NCT06296563","phase":"PHASE2","title":"Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC","status":"RECRUITING","sponsor":"Lei ZHAO","startDate":"2024-03-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":20},{"nctId":"NCT06364007","phase":"PHASE2","title":"HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC","status":"RECRUITING","sponsor":"Sulai Liu","startDate":"2024-03-03","conditions":"Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT05124002","phase":"PHASE4","title":"Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma","status":"RECRUITING","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2022-08-01","conditions":"Cholangiocarcinoma, Intrahepatic","enrollment":66},{"nctId":"NCT06210334","phase":"PHASE2","title":"HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)","status":"UNKNOWN","sponsor":"Li Xiao Wei","startDate":"2024-03","conditions":"Hepatocellular Carcinoma With PVTT","enrollment":54},{"nctId":"NCT06265883","phase":"","title":"Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2019-07-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":205},{"nctId":"NCT06199297","phase":"","title":"Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2021-03-02","conditions":"Hepatocellular Carcinoma","enrollment":188},{"nctId":"NCT06201065","phase":"PHASE3","title":"FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-12-26","conditions":"Hepatocellular Carcinoma","enrollment":200},{"nctId":"NCT05839197","phase":"PHASE2","title":"A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC","status":"UNKNOWN","sponsor":"Wan-Guang Zhang","startDate":"2023-05-05","conditions":"Macrotrabecular Massive Hepatocellular Carcinoma","enrollment":38},{"nctId":"NCT05833126","phase":"PHASE2","title":"Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation","status":"UNKNOWN","sponsor":"Shuhong Yi","startDate":"2023-12-03","conditions":"Recurrent Liver Cancer After Liver Transplantation","enrollment":25},{"nctId":"NCT06143579","phase":"PHASE2","title":"A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-12-15","conditions":"Potentially Resectable Hepatocellular Carcinoma","enrollment":48},{"nctId":"NCT06134193","phase":"PHASE2","title":"Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2023-11","conditions":"Carcinoma, Intrahepatic Cholangiocarcinoma, Gallbladder Cancer","enrollment":41},{"nctId":"NCT05250843","phase":"PHASE2, PHASE3","title":"TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2022-05-30","conditions":"Hepatocellular Carcinoma","enrollment":90},{"nctId":"NCT04191889","phase":"PHASE2","title":"A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-04-13","conditions":"C-staged Hepatocellular Carcinoma in BCLC Classification","enrollment":47},{"nctId":"NCT05099848","phase":"PHASE2","title":"A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2021-03-17","conditions":"Hepatocellular Carcinoma","enrollment":21},{"nctId":"NCT03722498","phase":"PHASE2","title":"Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE","status":"WITHDRAWN","sponsor":"Sun Yat-sen University","startDate":"2018-06-01","conditions":"Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT04962958","phase":"PHASE2","title":"Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-07-01","conditions":"Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasms","enrollment":30},{"nctId":"NCT05263219","phase":"PHASE3","title":"DEB-TACE+HAIC vs. HAIC for Large HCC","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2022-02-10","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":230},{"nctId":"NCT02973685","phase":"PHASE3","title":"HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-10-01","conditions":"HepatoCellular Carcinoma","enrollment":315},{"nctId":"NCT05886465","phase":"PHASE2","title":"HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-05-24","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT05866172","phase":"PHASE3","title":"HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-05-10","conditions":"Hepatocellular Carcinoma","enrollment":264},{"nctId":"NCT05753163","phase":"PHASE2","title":"Hepatic Arterial Infusion Chemotherapy Combined With Sintilimab and Regorafenib as Adjuvant Therapy for Colorectal Liver Metastasis Patients With a High Risk of Recurrent: a Single-arm, Phase II Study","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-08-02","conditions":"Colorectal Liver Metastasis","enrollment":44},{"nctId":"NCT05029973","phase":"PHASE2","title":"HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-05-10","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT05718492","phase":"NA","title":"A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-10-18","conditions":"Hepatocellular Carcinoma","enrollment":100},{"nctId":"NCT05617430","phase":"PHASE2","title":"Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2022-11-02","conditions":"Hepatocellular Carcinoma","enrollment":43},{"nctId":"NCT05582278","phase":"PHASE2","title":"HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC","status":"UNKNOWN","sponsor":"Wen Li","startDate":"2021-01-01","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT05535998","phase":"","title":"TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT","status":"COMPLETED","sponsor":"Yunfei Yuan","startDate":"2021-01-01","conditions":"Hepatocellular Carcinoma","enrollment":743},{"nctId":"NCT05524155","phase":"PHASE2","title":"Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-09","conditions":"Colorectal Cancer, Liver Metastasis","enrollment":30},{"nctId":"NCT05519410","phase":"PHASE2","title":"Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-08-23","conditions":"Resectable Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT05493332","phase":"PHASE2","title":"HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-09","conditions":"Hepatocellular Carcinoma","enrollment":93},{"nctId":"NCT05489692","phase":"","title":"HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2017-09-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":43},{"nctId":"NCT05313282","phase":"PHASE3","title":"A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-06-15","conditions":"C-staged Hepatocellular Carcinoma in BCLC Classification","enrollment":140},{"nctId":"NCT05002452","phase":"","title":"Observational Study of Factors Predicting Therapeutic Effects and Clinical Prognosis After HAIC for Locally Advanced HCC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-12-20","conditions":"Hepatocellular Carcinoma","enrollment":150},{"nctId":"NCT05214339","phase":"PHASE2","title":"A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-03-16","conditions":"Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma by BCLC Stage","enrollment":30},{"nctId":"NCT05311319","phase":"PHASE2","title":"HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-01-11","conditions":"Hepatocarcinoma","enrollment":70},{"nctId":"NCT05233358","phase":"NA","title":"HAIC Combined With Second-line \"Target Immunity\" for HCC With TACE Standard Treatment Low Response or Failure","status":"UNKNOWN","sponsor":"The Central Hospital of Lishui City","startDate":"2022-02-01","conditions":"Hepatocellular Carcinoma","enrollment":176},{"nctId":"NCT05121571","phase":"NA","title":"The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-04-21","conditions":"Hepatocellular Carcinoma","enrollment":114},{"nctId":"NCT04814043","phase":"PHASE2","title":"PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-04-20","conditions":"Hepatocellular Carcinoma","enrollment":57},{"nctId":"NCT05007587","phase":"EARLY_PHASE1","title":"Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-07-01","conditions":"Hepatocellular Carcinoma Stage IIIa","enrollment":60},{"nctId":"NCT04994236","phase":"PHASE2","title":"Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic Therapy","status":"UNKNOWN","sponsor":"Hui-Chuan Sun","startDate":"2021-07-01","conditions":"Hepatocellular Carcinoma","enrollment":49},{"nctId":"NCT04961970","phase":"PHASE3","title":"HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC","status":"UNKNOWN","sponsor":"Shi Ming","startDate":"2021-07-09","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":188},{"nctId":"NCT04947826","phase":"PHASE2","title":"Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-08","conditions":"Hepatocellular Carcinoma With Major Portal Vein Thrombosis","enrollment":100},{"nctId":"NCT04814030","phase":"PHASE2","title":"Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-04-20","conditions":"Hepatocellular Carcinoma","enrollment":80},{"nctId":"NCT04479527","phase":"PHASE2","title":"Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2021-04","conditions":"Hepatocellular Carcinoma","enrollment":34},{"nctId":"NCT03780049","phase":"PHASE3","title":"HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-10-01","conditions":"Hepatocellular Carcinoma","enrollment":304},{"nctId":"NCT02774187","phase":"PHASE3","title":"Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-05","conditions":"Hepatocellular Carcinoma","enrollment":247},{"nctId":"NCT03803254","phase":"PHASE2","title":"HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC","status":"WITHDRAWN","sponsor":"Sun Yat-sen University","startDate":"2019-01-03","conditions":"Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT03812770","phase":"PHASE2","title":"Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-08-04","conditions":"Hepatocellular Carcinoma","enrollment":150},{"nctId":"NCT02981498","phase":"PHASE2","title":"Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-06","conditions":"Hepatocellular Carcinoma","enrollment":35},{"nctId":"NCT03812783","phase":"PHASE2","title":"HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-11-05","conditions":"Hepatocellular Carcinoma","enrollment":100},{"nctId":"NCT03469479","phase":"PHASE3","title":"Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan Criteria","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-03-02","conditions":"Hepatocellular Carcinoma","enrollment":252},{"nctId":"NCT03468231","phase":"PHASE3","title":"HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-03-09","conditions":"Hepatocellular Carcinoma","enrollment":300},{"nctId":"NCT03048123","phase":"PHASE2","title":"HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-10-01","conditions":"Hepatocellular Carcinoma","enrollment":79},{"nctId":"NCT02987699","phase":"PHASE2","title":"Phase II Study of HAIC Using Cisplatin,Leucovorin and 5-Fluorouracil","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-11","conditions":"HepatoCellular Carcinoma","enrollment":54}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Oxaliplatin , fluorouracil, and leucovorin","FOLFOX"],"phase":"marketed","status":"active","brandName":"HAIC of FOLFOX","genericName":"HAIC of FOLFOX","companyName":"Tianjin Medical University Cancer Institute and Hospital","companyId":"tianjin-medical-university-cancer-institute-and-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HAIC (hepatic arterial infusion chemotherapy) of FOLFOX delivers chemotherapy directly into the hepatic artery to treat liver cancers with high local drug concentration. Used for Hepatocellular carcinoma, Advanced liver cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}